About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, February 13th, 2012

The QualityStocks
Daily Stock List


NanoViricides, Inc. (NNVC)

StockProfessors, PennyStockShark, and USA Market News reported recently on NanoViricides, Inc. (NNVC), PennyTrader Publisher, FeedBlitz did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NanoViricides, Inc. is developing a wide array of anti-viral therapeutics against several different viruses. The Company is a development stage enterprise that is creating special purpose nanomaterials for viral therapy. Their team possesses the combined expertise of having performed research, development, and regulatory processing for more than 25 drugs. Ten are approved and the rest are at various advanced clinical stages, at the team members' previous affiliations.

The Company's team has performed pioneering research in diverse areas that are at the forefronts of medical science and pharmaceutical technology. This includes polymeric micelles, multi-specific multi-targeting, anti-sense DNA, siRNA, ribozymes, and gene therapy.

The design of the Company's novel nanoviricide® class of drug candidates are to specifically attack enveloped virus particles and to dismantle them. NanoViricides has developed drug candidates against HIV, Dengue, and Adenoviral Epidemic Kerato-Conjunctivitis (EKC). These have all shown extremely high efficacies in pre-clinical animal studies. The Company has also developed drug candidates against Herpes that have shown strong efficacies in pre-clinical studies. These four commercially important programs are at pre-clinical candidate optimization stage. NanoViricides has a number of R&D programs against many other viruses including Ebola/Marburg and Rabies viruses.

Recently, they have declared a clinical drug candidate against influenza in their FluCide™ program - NV-INF-1. They have also requested a pre-IND Meeting with the US FDA to discuss the development plan for NV-INF-1. They are planning on two separate indications for NV-INF-1. One is a high strength dosage form for hospitalized patients with severe influenza. The other is a single course therapy for outpatients with less severe influenza. The Company has previously reported on the extremely high efficacies of their optimized FluCide™ drug candidates. They are now advancing one of the tested optimized FluCide candidates as the clinical drug candidate after performing substantial further analysis.

Today, NanoViricides' President, Dr. Anil Diwan, presented an overview of the Company at the 14th Annual BIO CEO and Investor Conference. The Conference is taking place at the Waldorf-Astoria Hotel in New York, New York.

NanoViricides, Inc. (NNVC) closed on Monday at $0.88, up 17.32%, on 489,017 volume with 181 trades. The average volume for the last 60 days is 264,352. The 52-week low/high is $0.52/$1.65.

Avcorp Industries Inc. (AVP.TO)

Today we are highlighting Avcorp Industries Inc. (AVP.TO), here at the QualityStocks Daily Newsletter.

Avcorp Industries Inc. designs and builds major airframe structures for some of the world's leading aircraft companies. These include Boeing, Bombardier, BAE Systems and Cessna. Avcorp offers integrated composite and metallic aircraft structures to aircraft manufacturers. The Company has over 50 years of experience, 483 skilled employees and 354,000 square feet of facilities. Avcorp Industries lists on the Toronto Stock Exchange; they have their headquarters in Delta, British Columbia.

The Company specializes in providing custom solutions for the design and manufacture of customers' tail, wing and other airframe structures. Their experienced engineering group provides custom-engineered designs and modifications to improve products and streamline manufacturing processes. Avcorp also holds numerous OEM (original equipment manufacturer) proprietary process approvals and NADCAP special process approvals. These are for AS7102 Heat Treating; AS7108 Chemical Processing; AS7114 Non-Destructive Testing; AS7117 Surface Enhancement; AS7118 Composites, and AS7101 Material Testing Laboratories. The Company has received MRB (Material Review Board) design authority approval by Bombardier and Cessna. This allows Avcorp's in-house engineers to approve certain changes in design.

Avcorp offers flight control surfaces, including tail structures, which consist of horizontal stabilizers and elevators, vertical stabilizers and rudders, and empennages. They also offer wing structures, including wing spars and center wing boxes. Additionally, they provide other structural assemblies, including fuel tanks, wheel-well fairings, and wing adapter plugs. Furthermore, they offer a range of services, which include assembly and repair, fabrication, kitting, sourcing, quality inspection, engineering, new product introduction, technology development, program management, project management, product support, product and tool design, parts fabrication, and research and development services.

Recently, at a ceremony held at their Delta, British Columbia facility, Avcorp Industries announced the delivery of the first F-35 Carrier Variant Outboard Wing (CV-OBW) production unit intended for in-service operation. The Honorable Julian Fantino, Associate Minister of National Defense (Canada), attended the ceremony along with special guests from BAE Systems and Lockheed Martin.

Avcorp Industries will deliver the first production unit direct to the final assembly line at Lockheed Martin Aeronautics in Fort Worth, Texas. Avcorp secured the F-35 Outboard Wing contract in 2009. They are currently the single source for this critical assembly. The Outboard Wing is the foldable portion of the wing on the carrier version of the F-35. Avcorp currently has the contract to 260 ship sets, with the opportunity to secure 340-plus ship sets of Outboard Wings for the F-35 (CV).

Avcorp Industries Inc. (AVP.TO) closed on Monday at $0.06, even with yesterday’s close. The 52-week low/high is $0.04/$0.11.

Unigene Laboratories, Inc. (UGNE)

SmallCapVoice reported recently on Unigene Laboratories, Inc. (UGNE), BullRally, HotOTC, CoolPennyStocks, Penny Invest, StockEgg, Stock Rich did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a portfolio of proprietary partnerships in this expanding drug class based on their Peptelligence™ platform. Peptides are a fast growing therapeutic class with over 130 programs currently in active development throughout the industry. To date, more than 50 peptide-based therapeutics have reached the market. Unigene Laboratories has their corporate headquarters in Boonton, New Jersey.

Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, peptide research and development expertise, and proprietary expertise. Core Peptelligence™ assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

In the third quarter of 2010, Unigene Laboratories completed a comprehensive business audit and situational analysis resulting in a new strategy for the Company, an organizational realignment with the creation of two highly focused strategic business units, Unigene Biotechnologies and Unigene Therapeutics, and the appointment of a new executive leadership team.

Unigene Biotechnologies is expanding the Peptelligence™ platform of peptide oral drug delivery and manufacturing assets and capabilities with the goal of establishing a portfolio of partnered opportunities. The Company's objective is to apply their Peptelligence™ platform to as many therapeutic peptide programs as possible and help their partners co-develop those peptides through advanced clinical testing and commercialization.

Unigene Therapeutics constitutes the Company's own pipeline of proprietary peptide development programs focused on metabolic disease and inflammation. In 2009, Unigene licensed their late-stage oral calcitonin formulation to Tarsa. Tarsa is a venture-financed company founded exclusively to conduct Phase 3 clinical testing and prepare Unigene's proprietary oral calcitonin formulation for commercialization. Unigene currently owns a 20 percent, fully diluted, stake in Tarsa, subject to possible future dilution.

Last week, Unigene Laboratories announced the expansion of their Biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes, Esq. to the position of Chief Business Officer and the appointment of Jane Pepper, M.B.A, Ph.D. to Senior Director, Business Development.

Unigene Laboratories, Inc. (UGNE) closed on Monday at $0.61, up 0.83%, on 33,002 volume with 12 trades. The average volume for the last 60 days is 82,534. The 52-week low/high is $0.37/$1.42.

Ace Marketing & Promotions, Inc. (AMKT)

The Green Baron and Stock Guru reported previously on Ace Marketing & Promotions, Inc. (AMKT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Ace Marketing & Promotions, Inc. (Ace) is a full-service integrated marketing solutions company that leverages technology. The Company offers an extensive spectrum of business solutions. These solutions include Branding and Branded Merchandise, Website Development (CMS), Direct Relationship Marketing and Mobile Marketing Solutions. Established in 1998, and headquartered in Valley Stream, New York, Ace lists on the OTC Bulletin Board.

Ace's proprietary Technology Platform, "AcePlace", is the heart of the Company's implementation strategy.  AcePlace eliminates the need for companies to rely on multiple vendors to put their marketing strategies to work. Ace's wholly owned subsidiary is Mobiquity Networks. Mobiquity is a leader in Proximity Marketing with proprietary Bluetooth and Wi-Fi integrated technology that establishes the benchmark for how multimedia messages undergo delivery to mobile devices.
Axxion is an online, proprietary Business Management Solution developed by Ace.  Axxion is a hybrid solution that Automates Order Processing and provides a Project Collaboration engine. It also serves as a company-wide interface for Document Storage and Management.
Ace also has the Team&Tour Digital Platform.  They developed a simple and unique online platform that allows artists, athletes, teams and iconic brands to create customized and personalized products based on their library of digital images.  Ace's innovative platform combines images with premier on-demand production facilities to create one-of-a-kind, digitally printed memorabilia. 

Last Thursday, Ace Marketing & Promotions announced that they plan to have the architecture for their proprietary mobile marketing solutions; "Mall-Offers Wi-Fi" and "malloffers.com" completed by the end of the first quarter 2012. The Company will start to rollout the solutions on their nationwide Mobiquity Network in the second quarter 2012. At present, Mobiquity Networks is operational in 67 malls across the United States and has access to approximately 92 million shopper visits monthly. The Company also expects to be in 75 malls by the end of the first quarter 2012.

The Mall-Offers Platform will list specials from retailers in each mall throughout the Mobiquity Network. The specials will be accessible on the secured Wi-Fi network that Mobiquity has already installed in each of their 67 malls across the United States. Malloffers.com is a website that aggregates all of the special offers, coupons and discounts offered by all of the participating retailers in all of the malls within the Mobiquity Network.

Ace Marketing & Promotions, Inc. (AMKT) closed on Monday at $0.75, down 11.76%, on 15,000 volume with 6 trades. The average volume for the last 60 days is 12,599. The 52-week low/high is $0.16/$1.85.

Ironclad Performance Wear Corp. (ICPW)

We are reporting on Ironclad Performance Wear Corp. (ICPW), here at the QualityStocks Daily Newsletter.

Ironclad Performance Wear Corp. is a leader in high-performance task-specific work gloves. The Company created the performance work glove category in 1998. They continue to take advantage of their leadership position in the safety, construction and industrial markets. This is by way of the design, development and distribution of specialized task-specific gloves for industries such as oil & gas extraction, automotive, and police, fire, first-responder and military. Ironclad Performance Wear lists on the OTC Bulletin Board. The Company has their corporate headquarters in El Segundo, California.

Additionally, Ironclad has extended their product line into the outdoor sports and lifestyle markets, with gloves designed specifically for hunters and campers.  The Company engineers and manufactures their products with a focus on innovation, design, advanced material science and durability. The Company's gloves and apparel are available through industrial suppliers, hardware stores, home centers, lumberyards, and sporting goods retailers across the country. They are available through authorized distributors in North America, Europe, Australia, New Zealand and Asia.

Ironclad has developed, and owns, 74 Patents and Trademarks globally. These exclusive properties are a part of the Company's Advanced Glove Technology (AGT), which can be seen in virtually every glove Ironclad sells. The Company's mission is to design, market and deliver the best technically advanced task-specific performance work gloves for the Industrial Athlete™.

The Company's patents range from ergonomically designed palm patterns to proprietary technical engineering, features and design. Ironclad uses premier materials in their products. They collaborate with leading suppliers of innovative materials and production facilities. Ironclad Performance Wear currently offers 78 styles of work gloves, priced between $14 and $60 per pair. In addition to gloves branded exclusively as "Ironclad", they design and market co-branded gloves under the Snap-on, Red Wing, Realtree, and 5.11 Tactical and Coleman names.

The Company plans to increase their domestic revenues by leveraging their relationships with existing retailers and industrial distributors, including "Big Box," automotive and sporting goods retailers. They also plan to increase their product offerings in new and existing locations, and introduce new products, developed and targeted for specific customers and/or industries.

Ironclad Performance Wear Corp. (ICPW) closed on Monday at $0.27, up 10.42%, on 65,800 volume with 13 trades. The average volume for the last 60 days is 60,627. The 52-week low/high is $0.07/$0.29.

PowerVerde, Inc. (PWVI)

We are highlighting PowerVerde, Inc. (PWVI), here at the QualityStocks Daily Newsletter.

Headquartered in Glendale, Arizona, PowerVerde, Inc. manufactures advanced renewable electric power generator systems. These consist of pressure expansion motors operating on any adequate heat or pressure source. These systems make electricity without fossil fuel - from any low-grade heat source or adequate pressure forum. PowerVerde is an environmentally friendly green company producing zero emissions or waste stream byproducts. The Company's shares trade on the OTCBB.

The heart of all the Company's electrical generation systems is a Gas Expansion Motor (GEM). It uses a working fluid that undergoes heating until it flashes into a high-pressure gas, much like steam engines powered by boiling water. The difference is the working fluid in the PowerVerde systems is an organic fluid that changes into a gas at a much lower temperature (160F). This means that the heat to boil the fluid can be supplied by low temperature solar panels, by low temperature waste heat, by low-grade geothermal wells or even by burning biomass.

In September 2011, PowerVerde entered into a distribution/manufacturing agreement with Newton Investments B.V. d/b/a Newton Greenpower of the Netherlands to distribute and manufacture their unique renewable waste heat system called the Liberator. This is the agreement contemplated by the binding letter of intent between the parties announced in February 2011.

The agreement gives Newton the exclusive right to manufacture the Liberator system and distribute it in all European Union countries, initially focusing on Holland, Belgium, Scandinavia and Germany. Under the agreement, Newton has arranged the manufacture of the Liberator at Autonational, a Dutch-based engineering/manufacturing facility. The agreement calls for annual minimum quotas beginning in the second year and a royalty paid on all systems sold.

Last Friday, PowerVerde announced the completion of a private offering of 500,000 restricted shares of their common stock. This is to certain accredited European investors at $1.00 per share, before placement fees and offering expenses. All shares were offered by the Company.

PowerVerde anticipates using the net proceeds of the offering for general corporate purposes. This includes research and development expenses, continued development of the Liberator waste heat energy system and the advancement of their business model offering electric green power systems to end users globally.

PowerVerde, Inc. (PWVI) closed on Monday at $1.23, up 2.50%, on 1,057 volume. The average volume for the last 60 days is 4,757. The 52-week low/high is $0.51/$4.00.

Topaz Resources, Inc. (TOPZ)

OTCReporter, Wise Alerts, Topgun stockpicks, The Stock Psycho, Stock exploder, Penny Stock Ryder, ItsAllBull.net, and HyperGrowthStock reported previously on Topaz Resources, Inc. (TOPZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Topaz Resources, Inc. is an independent oil and natural gas exploration, development and production company. They are focusing on production, acquisitions and developmental drilling opportunities within proven producing areas of north, central and west Texas. The Company's immediate capital program includes aggressively drilling on their Barnett Shale acreage and the consolidation, acquisition and enhancement of targeted properties. Topaz Resources has their headquarters in Denton, Texas.

The Topaz Resources team includes five key professionals that collectively represent more than 150 years of experience in all aspects of developing and managing energy projects and in running private and public companies. The Company's team has been involved in operating well and field activities, in building and running drilling rigs, in leasing mineral rights and in attracting appropriate financing.

Topaz has grouped their assets and projects of interest into three project areas. One is Production and Leasehold Acquisitions. This includes oil and gas reserve, production, acreage, and development opportunities. Another project area is Barnett Gas of 1850 +/- gross acres. This is Barnett gas drilling and acreage in Wise and Denton Counties in Texas. Their acreage is surrounded by existing production and current drilling activity and is serviced by existing gathering systems and pipeline infrastructure. The Barnett has become one of the biggest natural gas plays and drilling booms in the continental U.S. and the largest producing gas field in Texas.

The third project area is Barnett Oil of 950 +/- gross acres. This is Barnett oil/gas drilling and acreage in Montague County in Texas. In general, Barnett production in the core of the play in Wise and Denton Counties tends to be dry natural gas. Continued improvements in completion techniques have extended the Barnett play toward the northwest into Montague County. This is where production tends to include oil. The Topaz Resources immediate work plan includes drilling and completing one to three Barnett horizontal wells in the area.

Topaz Resources, Inc. (TOPZ) closed on Monday at $0.01, up 16.28%, on 411,700 volume with 27 trades. The average volume for the last 60 days is 241,543. The 52-week low/high is $0.0003/$0.02.

Lincoln Mining Corp. (LMG.V)

We are highlighting Lincoln Mining Corp. (LMG.V) today, here at the QualityStocks Daily Newsletter.

Lincoln Mining Corp. is a Canadian precious metals exploration and development company. They have a number of projects in various stages of exploration and development. These include the Pine Grove gold property, the Oro Cruz gold property in California and the La Bufa gold-silver property in Mexico. In the United States, they operate under Lincoln Gold US Corp., a Nevada corporation. Lincoln Mining has their headquarters in Vancouver, British Columbia. They also have an office in Carson City, Nevada.

One of Lincoln Mining's immediate objectives is to achieve gold production at the advanced-stage Pine Grove Property in Lyon County, Nevada. On December 8, 2011, the Company announced that they obtained a positive Preliminary Economic Assessment NI 43-101 technical report (PEA) on the Pine Grove gold project.  Combined Measured and Indicated gold resources within design pit shells for the Wheeler and Wilson deposits contain 3,470,000 tons grading 0.042 opt (1.44 g/t) gold at a cutoff grade of 0.007 opt gold (145,000 ozs gold).

The Oro Cruz project in Imperial County, California, is Lincoln Mining's most recent acquisition. In February 2010, they executed an agreement with ADGIS, Inc. to acquire 20 lode mineralization claims that cover the Oro Cruz gold deposit. Subsequently, Lincoln Mining has staked additional claims and the Oro Cruz project now consists of 151 lode claims covering approximately 3,000 acres.

The Company also has their La Bufa Property. This project is an early to mid-stage gold-silver exploration project located in the historical Guadalupe y Calvo mining district within the Sierra Madre mineral belt in southwestern Chihuahua State. Lincoln Mining controls a large land position that covers most of an 11 km long mineral trend.

Earlier this month, Lincoln Mining announced that further to their news release of January 30, 2012, they plan to increase their non-brokered private placement to up to 4,666,667 units at a price of $0.075 per unit for total proceeds of up to $350,000. The Company intends to use the proceeds raised from the private placement to advance the work programs on their mineral projects and for general working capital purposes.  

Lincoln Mining Corp. (LMG.V) closed on Monday at $0.06, even with yesterday’s close, on 59,000 volume. The 52-week low/high is $0.07/$0.27.


The QualityStocks
Company Corner


Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0110, up 37.50%, on 1,924,000 volume with 39 trades. The stock’s average daily volume over the past 60-day daily average volume is 139,974 with a 52-week low/high of $0.001/$0.0205.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings wholly-owned subsidiary Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

Consorteum Holdings Completes Acquisition of Tarsin Inc.

Consorteum Holdings, Inc. Announces Lead Spokesman for the First Nations MasterCard Program

Beacon Enterprise Solutions Group, Inc. (BEAC)

The QualityStocks Daily Newsletter would like to spotlight Beacon Enterprise Solutions Group, Inc. (BEAC). Today, Beacon Enterprise Solutions Group, Inc. closed trading at $0.32, off by 3.03%, on 142,500 volume with 15 trades. The stock’s average daily volume over the past 60-days is 58,170 with a 52-week low/high of $0.14/$0.70.

Beacon Enterprise Solutions Group, Inc. (BEAC) specializes in designing, implementing and managing high performance Information Technology Systems ("ITS") infrastructure solutions. Offering national, multi-national and global, turnkey ITS infrastructure solutions, the company is capable of delivery professional services to Fortune 1000 and large multi-site firms as they increasingly single source and outsource to reduce costs while optimizing critical planning, design, program, project and construction management and managed services.

Leveraging standardization, rapid mobilization and a just-in-time professional services approach, Beacon Enterprise Solutions serves as a single source for national, multi-national and global enterprise clients, including special practices focused on data centers, campuses, smart buildings, outside plant, wireless systems and other technology-based applications and projects. Clients are provided with consistent and predictable results anywhere in the world. The company's solutions allow clients to focus on their core businesses without the distraction of having employees spend valuable time on services that Beacon can provide on any continent, in any country using any language.

Headquartered in Louisville, Kentucky, with regional headquarters in Cincinnati, Ohio, Dublin, Ireland, and Prague, Czech Republic, in addition to personnel located throughout the United States and Europe, Beacon Enterprise Solutions services a diverse range of clients. For more than 30 years, the company has enabled businesses in a variety of vertical markets to dramatically reduce costs, enable global standardization, manage day-to-day technology systems moves, adds and changes, and take on major projects – all under a single national, multi-national or global agreement.

Beacon Enterprise Solutions has carefully assembled a seasoned management team and operating strategy to maximize organic growth and new business development across multiple vertical markets. More than 4,000 companies, from small businesses to Fortune 50 firms, have chosen the company's solutions. Disclaimer

Beacon Enterprise Solutions Group, Inc. Blog

Beacon Enterprise Solutions Group, Inc. News:

Beacon Enterprise Solutions Reports 36% Increase in Blended Project Funnel

Beacon Enterprise Solutions Hires Industry Sales Veteran

Beacon Enterprises Solutions Group, Inc. Announces 97% Increase in Gross Profits and 51% Increase in Net Sales for Fiscal Q1 2012

FluoroPharma Medical, Inc. (FPMI)

The QualityStocks Daily Newsletter would like to spotlight FluoroPharma Medical, Inc. (FPMI). Today, FluoroPharma Medical, Inc. closed trading at $0.89, off by 5.32%, on 29,275 volume with 9 trades. The stock’s average daily volume over the past 60-day daily average volume is 24,137 with a 52-week low/high of $0.56/$2.15.

FluoroPharma Medical, Inc. (FPMI) is a cutting edge provider of information, content distribution, media management and secure communications to the hospitality industry. The company's state of the art digital technology platform and Internet Protocol (IP) infrastructure presents hotels with a valuable opportunity to generate new revenue while enhancing guests' experiences by providing content that is more relevant to their unique interests.

The company's integrated platform stands far beyond the competition, offering unparalleled guest services such as messaging, folio review, express check outs, energy management and other personalized services while providing the traditional services of Free to Guest (FTG) programming, Video-On-Demand programming, a highly secured high speed internet service and many other interactive services such as gaming.

By combining TV and the web world through unparalleled IPTV/HDTV service, hotels are able to generate additional income through commercial spots, advertisements of local tourist services, hotel promotions and more. Features of the platform includes remote administration, support for more than twenty languages, easy installation and a comprehensive hotel services menu capable of providing detailed information about the hotel and upcoming activities, billing information, room service, guest messages and wake-up services.

The system's architecture consists of a Network Operating Center (NOC) and local hotel servers connected through a point-to-point broadband network. As each guest accesses the network, the resulting traffic generated undergoes analysis based on various criteria. This includes behavioral, geographical, seasonality, and more. Using this data, hotels are able to ensure advertisers maximum value for their advertising budget. Disclaimer

FluoroPharma Medical, Inc. Company Blog

FluoroPharma Medical, Inc. News:

FluoroPharma to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference

FluoroPharma Announces Addition to the Board of Directors Reflecting Strong Focus on the Future

FluoroPharma Announces Aggregate of $7M Capital Raise in 2011

TiVUS, Inc. (TIVU)

The QualityStocks Daily Newsletter would like to spotlight TiVUS, Inc. (TIVU). Today, TiVUS, Inc. closed trading at $0.0002, even for the day, on 4,020,927 volume with 2 trades. The stock’s average daily volume over the past 60-day daily average volume is 22,976,883 with a 52-week low/high of $0.0001/$0.06.

TiVUS, Inc. (TIVU) is a cutting edge provider of information, content distribution, media management and secure communications to the hospitality industry. The company's state of the art digital technology platform and Internet Protocol (IP) infrastructure presents hotels with a valuable opportunity to generate new revenue while enhancing guests' experiences by providing content that is more relevant to their unique interests.

The company's integrated platform stands far beyond the competition, offering unparalleled guest services such as messaging, folio review, express check outs, energy management and other personalized services while providing the traditional services of Free to Guest (FTG) programming, Video-On-Demand programming, a highly secured high speed internet service and many other interactive services such as gaming.

By combining TV and the web world through unparalleled IPTV/HDTV service, hotels are able to generate additional income through commercial spots, advertisements of local tourist services, hotel promotions and more. Features of the platform includes remote administration, support for more than twenty languages, easy installation and a comprehensive hotel services menu capable of providing detailed information about the hotel and upcoming activities, billing information, room service, guest messages and wake-up services.

The system's architecture consists of a Network Operating Center (NOC) and local hotel servers connected through a point-to-point broadband network. As each guest accesses the network, the resulting traffic generated undergoes analysis based on various criteria. This includes behavioral, geographical, seasonality, and more. Using this data, hotels are able to ensure advertisers maximum value for their advertising budget. Disclaimer

TiVUS, Inc. Company Blog

TiVUS, Inc. News:

TiVUS' Ad-Insertion Attracts Diverse Range of Advertisers

TiVUS' First Ad-Insertion Revenues Begin - Hotel TV advertising embraced by local merchants

TiVUS Commences Live Hotel TV Ad-Insertions

FluoroPharma Medical, Inc. (FPMI) Continues to Move New Products Forward

Turning a good idea into a money making product can be a formidably expensive project, especially when dealing with medical substances to be introduced to the human body. FluoroPharma, developer of medical diagnostic imaging agents for use with PET (positron emission tomography) scanning, is believed to be in a strong position to accomplish exactly that with its two primary imaging assets, CardioPET and BFPET. CardioPET is an imaging agent designed for cardiac viability assessment, detecting regions of metabolic insufficiency. BFPET is designed for myocardial perfusion imaging, measuring cardiovascular blood flow. The company is about to take both of these products through phase II testing, considered an important step for attracting partners.

FluoroPharma has made significant progress in the last couple of years, advancing its pipeline of products and solidifying its finances, primarily through a reverse merger with a shell company in May of 2011. The result has been an expanded investor base. The reverse merger also helped raise money to meet the terms of the company’s licensing agreement with Massachusetts General Hospital, the source of key technology. FluoroPharma announced in December that it had raised an additional $1 million from investors, for a 2011 total of over $7 million.

Cardiology is an especially promising market. Nuclear cardiologists are anxious for new tracers, and cardiology is one of the focal points for FluoroPharma agents. PET molecular imaging technology allows doctors and drug developers to create the highest resolution images of internal structures, plus, unlike most imaging, it can provide a real time view of molecular metabolism, revealing what’s really happening in the body down to the cellular level. Although PET technology is currently used mostly for cancer diagnosis and monitoring, FluoroPharma believes that there is a huge potential market for cardiovascular and neurological applications. Cardiovascular disease is still the number one killer, and agents that can help in related diagnosis and drug development could be the next hot ticket.

For more information, see the company website at www.FluoroPharma.com

PositiveID (PSID) Achieves Positive Preliminary Results for Glucose-sensing Diabetes Device

PositiveID Corp., a developer of medical technologies for diabetes management, today announced that preliminary results from its biotransport research study with the Diabetes Research Institute (DRI) at the University of Miami demonstrate positive data for the company’s GlucoChip ™.

PositiveID’s GlucoChip is a glucose-sensing implantable microchip, currently under development with RECEPTORS LLC, for individuals with diabetes. The company reports that preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids.

“These first studies were successfully completed with the demonstration that a glucose tracer readily enters the device from surrounding body fluids. We are currently implementing the next phase of these studies, which will focus in more detail on both the kinetics of transport, which will determine how quickly the device will be able to respond to changes in glucose levels in the body, and on the long-term biocompatibility of the membrane,” Robert E. Carlson, Ph.D., RECEPTORS president and chief scientific officer stated in the press release.

PositiveID chairman and CEO William J. Caragol said by achieving the positive results, the company is on-track to overcoming “significant” development challenges.

“We believe the preliminary results from our research study at the DRI are not only positive but also promising as we proceed with our development. By achieving early confirmation that the membrane materials we will use with GlucoChip allow for movement of glucose from fluids in the body into the glucose-sensing device, we have begun to eliminate one of the significant hurdles of this potentially ground-breaking development project,” Caragol stated.

PositiveID and partner RECEPTORS LLC have completed prototype development of a stable and reproducible, closed-cycle continuous glucose-sensing system. Should they achieve continued positive results from the biocompatibility and biotransport, PositiveID will be on-track to complete development of GlucoChip.

For more information visit www.PositiveIDCorp.com

Celsion Corp. (CLSN) Enrolls First Patient in Phase II Study for Colorectal Liver Metastases Treatment

Leading oncology drug development company Celsion Corp. today announced it has enrolled its first patient in a randomized phase II study of ThermoDox, the company’s lead product candidate. ThermoDox is a heat-activated liposomal encapsulation of doxorubicin that, in combination with radiofrequency ablation (RFA), is being tested for the treatment of colorectal liver metastases (CRLM).

Up to 88 patients diagnosed with colorectal cancer metastasized to the liver are expected to be enrolled in the multicenter phase II study. The patients will be randomized to receive liver tumor treatment that is either includes RFA plus ThermoDox or RFA alone. Leading North American research institutions will be included in the phase II study, including Montefiore-Einstein Center for Cancer Care in New York City, which is where Lead Principal Investigator Dr. Steven K. Libutti serves as director.

More than 141,000 new cases of colorectal cancer were diagnosed in 2010, with 51,000 colorectal cancer deaths, according to the American Cancer Society. As many as 25 percent of colorectal cancer patients present with liver metastases, and 50 percent develop liver metastases within five years. The liver provides a favorable environment for growth and proliferation of metastases for cancers of the colon and rectum, and addressing these metastases enables improvement of three- and five-year survival rates for patients with this type of cancer. RFA alone is often limited to treating smaller metastases within the liver, but the addition of ThermoDox as adjuvant therapy has shown early clinical promise in treating larger tumors and multifocal disease. The primary endpoint of the phase II study is based on one year local tumor recurrence, with secondary endpoints of time to progression and overall survival.

Celsion Corp. is a leading oncology company specializing in the development and commercialization of cancer drugs. Celsion has research, license and commercialization agreements with such leading institutions as the National Institutes of Health, Duke University, University of Hong Kong, UCLA Department of Medicine, the University of Pisa, Kyungpook National University Hospital, and the Beijing Cancer Hospital.

For further information about the company, visit www.celsion.com

MedPro Safety Products, Inc. (MPSP) Survey Finds Ample Support for their Prefilled Cartridge Safety Syringe Drug Delivery Platform

Today, MedPro Safety Products, the Lexington, Kentucky-based developer of innovative safety-focused products that cut across multiple product categories in medication delivery and blood collection, reported that the results of a recent survey of 497 pharmacy professionals (conducted at the American Society of Health System Pharmacists Mid-Year Clinical Meeting in Dec 2011) suggest significant interest exists for a new pre-filled drug delivery platform.

These results are excellent news for MPSP, which has developed an impressive array of medical devices/products for phlebotomy and drug delivery applications. MPSP products are designed to incorporate automatic and/or semi-automatic activation systems, a feature which has been shown to be effective in reducing healthcare worker needlestick injury, as well as eliminating the risk of accidental reuse.


• VACUETTE® PREMIUM Safety Needle System Tube-Touch – an integrated, multiple sample needle and safety shield which automatically releases on insertion, then immediately covers the needle after blood collection (available in 20G, 21G, and 22G)

Drug Delivery

• Prefilled Passive Safety Syringe (MedPro Drug Delivery Platform component) – prefilled cartridge system with safety shield that automatically releases during injection, covering the needle immediately after drug delivery (available in 0.5ml – 3ml range)
• Prefilled IV Shuttle (MedPro Drug Delivery Platform component) – compatible with all needle free valves on the market, the prefilled IV shuttle was designed for nurses and features an audible click that confirms drug delivery (available in 0.5ml – 10ml range)
• MedPro Passive Safety Hypodermic Syringe – automatic safety shield mechanism, available for CM, IM, and ID injections, with a design that allows a syringe barrel for patient labeling data

The Company is preparing to launch its prefilled, fully-passive safety syringe/IV shuttle platform and is actively seeking commercialization partners. The only real options out there right now for healthcare professionals are considered hard to use, difficult to learn, and ultimately too complex in terms of parts/steps. Extant offerings just aren’t a realistic solution for the hectic work environment healthcare professionals must contend with on a daily basis and these complex devices even contribute to needlestick injury because of their failings. MedPro is ready to change the game with their innovative drug delivery system and the company will be exhibiting the platform in Paris, France, this Feb 15-16, at the drug packaging/delivery industry event PharmaPack.

Chairman and CEO of MPSP, Wm. Craig Turner, underscored the Company’s interest in expanding strategic partnerships, in order to fully maximize commercial potential of the robust pipeline MPSP has developed, while broadening MedPro’s scope from phlebotomy sharps to include the cutting-edge in ultra-safe drug delivery and medical other devices.

For more information on the survey, or on MedPro Safety Products, Inc. please visit the Company’s website at: www.MedProSafety.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





Nebula Stocks


PennyTrader Publisher

By The Numbers Charts

Daily Sponsors

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251